NCT05079672

Brief Summary

Acute pain is one of the complications after cardiothoracic surgeries . It can delay patients´recovery and may increase patients´morbity and mortality. This study intends to evaluate Dexmedetomidine, a highly selective α- 2 receptor agonist, that is currently applied safely and efficiently in intraoperative cardiac surgery. It has analgesic, sedative, anxiolytic and sympatholytic properties, without respiratory- depressant effect. The aim of this study is to investigate whether the intraoperative use of dexmedetomidine is better than the standard analgesia used in the intraoperative period to reduce pain and the consequences of it.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
102

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Oct 2021

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 3, 2021

Completed
4 days until next milestone

Study Start

First participant enrolled

October 7, 2021

Completed
8 days until next milestone

First Posted

Study publicly available on registry

October 15, 2021

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 10, 2022

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

October 10, 2023

Completed
Last Updated

October 20, 2021

Status Verified

October 1, 2021

Enrollment Period

1 year

First QC Date

October 3, 2021

Last Update Submit

October 14, 2021

Conditions

Keywords

DexmedetomidineCardiac surgeryAnalgesia

Outcome Measures

Primary Outcomes (1)

  • Pain 24 hours after cardiac surgery.

    The assessment of pain intensity, in patients with self- reporting, will be done by: Numeric Rating Scale (NRS) 0- 10. Possible score range from 0 (no pain) to 10 (worst pain ever ). The assessment of pain intensity, in patients on mechanical ventilation, will be done by: Behavioral Pain Scale, through facial expression (score 1-4), upper limb movement (score 1-5) and compliance with mechanical ventilation (score 1-3). Possible score range from 3 (no pain) to 12 (maximum pain).

    24 hours after the cardiac surgery.

Secondary Outcomes (1)

  • Opioid consumption.

    During the first 24 hours.

Other Outcomes (4)

  • Time from the end of surgery to extubation.

    During the first 24 hours.

  • Bleeding.

    During the first 24 hours.

  • Cardiac arrhythmias.

    During the first 24 hours.

  • +1 more other outcomes

Study Arms (2)

Group Dexmedetomidine

ACTIVE COMPARATOR

The patient will receive Dexmedetomidine, at the rate of 0,3μg/ kg/h, in continuous intravenous infusion from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.

Drug: Dexmedetomidine

Group 0,9% Saline

PLACEBO COMPARATOR

The patient will receive a 0,9% saline, in continuous intravenous infusion, from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.

Drug: 0,9% Saline

Interventions

Dexmedetomidine injectable solution, at the rate of 0,3μg/ kg/h, will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by-pass.

Group Dexmedetomidine

Saline 0,9% will be infused from the initiation of the anesthesia up to the end of the procedure, except during the cardiopulmonary by- pass.

Group 0,9% Saline

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients at least 18 years old and who are undergoing cardiac procedures (coronary artery bypass, valve replacement or combined procedure), with cardiopulmonary by- pass.

You may not qualify if:

  • Congenital heart disease
  • Infective endocarditis
  • Acute myocardial infarction (\<two weeks)
  • Pregnancy
  • Cancer
  • Left ventricle ejection fraction \< 40%
  • Cardiogenic shock
  • Emergent procedure
  • Use of vasopressor and/or inotrope, in the preoperative
  • Liver disfunction
  • Renal replacement therapy
  • Nephrectomy
  • Previous renal transplantation
  • Patients who are participating in another clinical research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Nova Esperança University Hospital

João Pessoa, Paraíba, 58.015-345, Brazil

RECRUITING

Heart Institute (InCor), Univ. of Sao Paulo Medical School

São Paulo, 05403000, Brazil

RECRUITING

Related Publications (10)

  • Kundra S, Taneja S, Choudhary AK, Katyal S, Garg I, Roy R. Effect of a low-dose dexmedetomidine infusion on intraoperative hemodynamics, anesthetic requirements and recovery profile in patients undergoing lumbar spine surgery. J Anaesthesiol Clin Pharmacol. 2019 Apr-Jun;35(2):248-253. doi: 10.4103/joacp.JOACP_338_18.

    PMID: 31303717BACKGROUND
  • Bielka K, Kuchyn I, Babych V, Martycshenko K, Inozemtsev O. Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic small es, Cyrillicholecystectomy: a randomized controlled study. BMC Anesthesiol. 2018 Apr 20;18(1):44. doi: 10.1186/s12871-018-0508-6.

    PMID: 29678158BACKGROUND
  • Talke P, Chen R, Thomas B, Aggarwall A, Gottlieb A, Thorborg P, Heard S, Cheung A, Son SL, Kallio A. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg. 2000 Apr;90(4):834-9. doi: 10.1097/00000539-200004000-00011.

    PMID: 10735784BACKGROUND
  • Aho MS, Erkola OA, Scheinin H, Lehtinen AM, Korttila KT. Effect of intravenously administered dexmedetomidine on pain after laparoscopic tubal ligation. Anesth Analg. 1991 Aug;73(2):112-8. doi: 10.1213/00000539-199108000-00002.

    PMID: 1854025BACKGROUND
  • Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol. 2008 Aug;21(4):457-61. doi: 10.1097/ACO.0b013e328305e3ef.

    PMID: 18660652BACKGROUND
  • Kotfis K, Strzelbicka M, Zegan-Baranska M, Safranow K, Brykczynski M, Zukowski M, Ely EW; POL-BPS Study Group. Validation of the behavioral pain scale to assess pain intensity in adult, intubated postcardiac surgery patients: A cohort observational study - POL-BPS. Medicine (Baltimore). 2018 Sep;97(38):e12443. doi: 10.1097/MD.0000000000012443.

    PMID: 30235728BACKGROUND
  • Habibi V, Kiabi FH, Sharifi H. The Effect of Dexmedetomidine on the Acute Pain After Cardiothoracic Surgeries: A Systematic Review. Braz J Cardiovasc Surg. 2018 Jul-Aug;33(4):404-417. doi: 10.21470/1678-9741-2017-0253.

    PMID: 30184039BACKGROUND
  • Hall R. Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery. J Cardiothorac Vasc Anesth. 2013 Oct;27(5):983-1033. doi: 10.1053/j.jvca.2012.09.013. Epub 2012 Dec 29. No abstract available.

    PMID: 23276596BACKGROUND
  • Brandao PG, Lobo FR, Ramin SL, Sakr Y, Machado MN, Lobo SM. Dexmedetomidine as an Anesthetic Adjuvant in Cardiac Surgery: a Cohort Study. Braz J Cardiovasc Surg. 2016 May-Jun;31(3):213-218. doi: 10.5935/1678-9741.20160043.

    PMID: 27737403BACKGROUND
  • Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY; MAC Study Group. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. Anesth Analg. 2010 Jan 1;110(1):47-56. doi: 10.1213/ane.0b013e3181ae0856. Epub 2009 Aug 27.

    PMID: 19713256BACKGROUND

MeSH Terms

Conditions

Heart DiseasesCoronary Artery DiseaseHeart Valve DiseasesPainAgnosia

Interventions

Dexmedetomidine

Condition Hierarchy (Ancestors)

Cardiovascular DiseasesCoronary DiseaseMyocardial IschemiaArteriosclerosisArterial Occlusive DiseasesVascular DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Luiz Antônio Machado César

    University of Sao Paulo

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Luiz Antônio Machado César

CONTACT

Lígia Ferreira dos santos

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associated Professor of Cardiology

Study Record Dates

First Submitted

October 3, 2021

First Posted

October 15, 2021

Study Start

October 7, 2021

Primary Completion

October 10, 2022

Study Completion

October 10, 2023

Last Updated

October 20, 2021

Record last verified: 2021-10

Data Sharing

IPD Sharing
Will not share

This will be decided, after data collection stars.

Locations